OakChart

Solid Biosciences Inc

SLDBHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 10:26 AM ET

7.59+0.41 (5.79%)
2026-11-11 16:27 CET
Market cap
800.25 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-215.27 USD m
Free cash flow, TTM
-200.30 USD m
EPS diluted, TTM
-1.78
P/E
-
Compare

Price

SLDB against its 20, 50 and 200-day averages
2050200beatmiss
6.008.0010.007.4M14.8MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26SLDBclose 7.5920-day 6.3350-day 7.33200-day 7.687.59

33.8% under 11.45 on 6 Jul 2026. Last 15 sessions, 32.9% high to low

Profile

SLDB
52-week range, 48% of the way up
4.0511.45

Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.

IndexRUT
Employees121
IPOJan 26, 2018
Beta2.60
ATR, 14d0.47
Rel volume1.22
Short float14.61%
Insider own18.41%
Inst own87.15%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap846.57M
Enterprise Value516.62M
Income-215.27M
Sales0.00M
Book/sh3.07
Cash/sh3.13
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees121
IPOJan 26, 2018

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B2.47
P/C2.42
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio11.99
Current Ratio11.99
Debt/Eq0.06
LT Debt/Eq0.05
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.78
EPS next Y-1.59
EPS next Q-0.39
EPS this Y16.55%
EPS next Y4.51%
EPS next 5Y18.91%
EPS past 3/5Y41.79% 39.94%
Sales past 3/5Y- -
EPS Y/Y TTM28.59%
Sales Y/Y TTM-
EPS Q/Q26.32%
Sales Q/Q-
EarningsNov 04 AMC
EPS/Sales Surpr.12.04% -

Ownership

Insider Own18.41%
Insider Trans-0.02%
Inst Own87.15%
Inst Trans11.54%
ROA-64.86%
ROE-76.87%
ROIC-59.89%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2019.90%
SMA503.45%
SMA200-1.24%
Trades-

Technical

Shs Outstand111.56M
Shs Float91.06M
Short Float14.61%
Short Ratio10.84
Short Interest13.30M
52W High11.45 -33.76%
52W Low4.05 87.28%
Volatility8.65% 8.00%
ATR (14)0.47
RSI (14)62.06
Beta2.60
Rel Volume1.22
Avg Volume1.23M
Volume279,532

Performance

Perf Week16.33%
Perf Month30.33%
Perf Quarter-16.46%
Perf Half Y2.78%
Perf YTD34.49%
Perf Year67.44%
Perf 3Y243.21%
Perf 5Y-76.59%
Perf 10Y-
Recom1.00
Target Price18.71
Prev Close7.17
Price7.59
Change %5.79%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Nov 09, 2026ResumedWWilliam BlairOutperform
Oct 15, 2026InitiatedUUBSBuy$20+163.7%
Sep 16, 2026InitiatedRRBC Capital MktsOutperform$18+137.3%
Aug 21, 2026ResumedTTruistBuy$20+163.7%
Mar 20, 2026InitiatedGGuggenheimBuy$26+242.8%
Dec 04, 2025InitiatedNNeedhamBuy$16+110.9%
Jun 26, 2025InitiatedCCitigroupBuy$14+84.6%
Jan 08, 2025InitiatedTTruistBuy$16+110.9%
Dec 13, 2024InitiatedWWedbushOutperform$16+110.9%
Dec 10, 2024InitiatedJJMP SecuritiesMkt Outperform$15+97.8%

Peers

Mkt cap
TickerCompanyMkt cap
SRPTSarepta Therapeutics Inc1.73B
RGNXRegenxbio Inc540.88M
DYNDyne Therapeutics Inc3.38B
WVEWave Life Sciences Inc677.82M
CAPRCapricor Therapeutics Inc600.57M
LXEOLexeo Therapeutics Inc253.24M
EWTXEdgewise Therapeutics Inc5.08B
RCKTRocket Pharmaceuticals Inc266.95M
TRDAEntrada Therapeutics Inc203.00M
PTCTPTC Therapeutics Inc5.35B

Insider trading

latest 14 of 49
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Brooks GabrielChief Medical OfficerOct 19 '26Sale5.624,37424,58297,241Oct 20 04:05 PM
Cumbo AlexanderPresident and CEOFeb 18 '26Sale5.8216,64496,923235,405Feb 18 09:38 PM
Brooks GabrielOfficerFeb 18 '26Proposed Sale5.825,56332,395Feb 18 09:35 PM
Cumbo AlexanderOfficerFeb 18 '26Proposed Sale5.8216,64496,923Feb 18 09:35 PM
Hanrahan JessieChief Regulatory OfficerFeb 18 '26Sale5.824,13424,07474,318Feb 18 09:34 PM
Hanrahan JessieOfficerFeb 18 '26Proposed Sale5.824,13424,074Feb 18 09:33 PM
Ganot IlanDirectorFeb 18 '26Sale5.822,65815,47827,474Feb 18 09:32 PM
Herzich PaulOfficerFeb 18 '26Proposed Sale5.823,61621,057Feb 18 09:32 PM
Ganot IlanDirectorFeb 18 '26Proposed Sale5.922,65815,748Feb 18 09:31 PM
Herzich PaulChief Technology OfficerFeb 18 '26Sale5.823,61621,05772,638Feb 18 09:31 PM
Howton David TChief Operating OfficerFeb 18 '26Sale5.827,46943,494105,077Feb 18 09:31 PM
Howton David TOfficerFeb 18 '26Proposed Sale5.827,46943,494Feb 18 09:30 PM
Tan KevinOfficerFeb 18 '26Proposed Sale5.825,40431,469Feb 18 09:28 PM
Tan KevinCFO & TreasurerFeb 18 '26Sale5.825,40431,46999,422Feb 18 09:25 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IBBiShares Biotechnology ETFAUM: 11.36B
DFASU.S. Small Cap Portfolio-ETF Class Shares-
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B

News

latest 14 of 206
  • Solid Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference (GlobeNewswire)
  • Solid Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference (GlobeNewswire) -5.21%
  • Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
  • Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich's Ataxia (GlobeNewswire)
  • Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026 (GlobeNewswire) +8.11%
  • Loading…
  • Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
  • Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
  • BioGene Therapeutics Inc. Appoints Ty Howton to Board of Directors (TMX Newsfile)
  • Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.48%
  • Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
  • Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
  • Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-0.360-0.409-0.3590.000.0014
2026Q22026-08-06-0.380-0.462-0.3810.000.0012
2026Q12026-05-12-0.520-0.429-0.5170.000.0013
2025Q42026-03-19-0.530-0.519-0.5260.000.0013
2025Q32025-11-03-0.480-0.439-0.4850.000.0013
2025Q22025-08-12-0.420-0.497-0.4190.000.0013
2025Q12025-05-15-0.590-0.555-0.5920.000.0012
2024Q42025-03-06-1.000-0.805-0.9970.000.0012
2024Q32024-11-06-0.790-0.668-0.7900.000.009
2024Q22024-08-13-0.610-0.664-0.6130.000.008
2024Q12024-05-09-0.640-0.640-0.6370.001.458
2023Q42024-03-13-0.998-1.023-0.9980.000.005
2023Q32023-11-08-1.050-1.182-1.0460.000.005
2023Q22023-08-14-1.251-1.370-1.2530.002.204
2023Q12023-05-16-1.540-1.612-1.5370.002.204
2022Q42023-03-23-0.790-1.505-0.7750.000.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-43.650-41.850-43.6430.000.00
2020FY-25.500-25.500-25.4990.000.00
2021FY-10.200-10.770-10.14213.6912.10
2022FY-10.100-6.829-10.1018.098.10
2023FY-4.830-4.762-4.8290.000.00
2024FY-3.060-2.937-3.0550.000.00
2025FY-1.990-2.116-1.9900.000.00
2026FY--1.661--0.00
2027FY--1.586--10.31
2028FY--1.061--105.46
2029FY--0.186--301.86
2030FY-0.976--582.26

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-058000.000.000.00
2026Q4S2026-11-048000.000.000.00
2026Q4S2026-09-228000.000.000.00
2026Q4S2026-08-079000.000.000.00
2026Q4S2026-07-309000.000.000.00
2026Q4S2026-05-1310000.000.000.00
2026Q4S2026-03-209000.000.000.00
2026Q4S2025-11-117000.000.000.00
2026Q4S2025-11-107000.000.000.00
2026Q4S2025-11-097000.000.000.00
2026Q4S2025-11-087000.000.000.00
2026Q4S2025-11-077000.000.000.00
2026Q4S2025-11-067000.000.000.00
2026Q4S2025-11-057000.000.000.00

Estimate history

EPS, annual-17.269-33.731-43.643-25.499-10.142-10.101-4.829-3.055-1.992-1.7808
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.79-0.997-0.592-0.419-0.485-0.526-0.517-0.381-0.357
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000013.628.0940000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual2.2772.3623.0665.667.35619.55720.38740.46878.968111.555
Period201720182019202020212022202320242025MRQ
Shares, quarterly38.9340.46877.49377.60377.88378.96898.395105.125111.555
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.008.0913.620.000.000.00
Cost of Goods Sold Incl. D&A1.671.642.462.582.412.963.922.821.57
Gross Profit-1.67-1.64-2.46-2.585.6910.66-3.92-2.82-1.57
Selling, General and Administrative Excl. Other220.08177.57127.27101.73100.0982.9182.54116.4974.12
Research and Development172.13140.3296.4376.5678.4258.7464.8894.7457.97
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-221.75-179.21-129.73-104.31-94.40-72.25-86.46-119.32-75.69
Interest Expense0.000.000.34------
Unusual Expense5.006.054.75-0.0612.050.001.940.000.00
Net Income Before Taxes-215.27-174.32-124.70-96.02-85.98-72.19-88.29-117.22-74.80
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-215.27-174.32-124.70-96.02-85.98-72.19-88.29-117.22-74.80
Net Income From Continuing Operations-215.27-174.32-124.70-96.02-85.98-72.19-88.29-117.22-74.80
Net Income-215.27-174.32-124.70-96.02-85.98-72.19-88.29-117.22-74.80
EPS (Recurring)-1.40-1.94-2.97-4.83-9.11-10.14-25.11-43.64-33.73
EPS (Basic, Before Extraordinaries)-1.78-1.99-3.06-4.83-10.10-10.14-25.50-43.64-33.73
EPS (Diluted)-1.78-1.99-3.06-4.83-10.10-10.14-25.50-43.64-33.73
EBITDA-220.08-177.57-127.27-101.73-92.00-69.29-82.54-116.49-74.12
Non-Operating Income (Expense)11.4810.9310.128.2420.470.070.122.100.89
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense23.4116.9110.527.627.5413.3711.6314.215.96
Price To Sales Ratio----5.6613.72---
Gross Margin----70.2578.24---
Operating Margin-----1,166.35-530.50---
Net Margin-----1,062.28-530.01---
Shares Outstanding111.5678.9740.4720.3919.567.365.663.072.36
Market Capitalization800.25800.25159.82123.89105.06193.10643.50204.64949.59

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.420.390.400.470.380.390.410.49
Gross Profit-0.42-0.39-0.40-0.47-0.38-0.39-0.41-0.49
Selling, General and Administrative Excl. Other57.2456.9956.9148.9447.6841.3139.6539.41
Research and Development43.5944.2746.1438.1338.8632.4130.9130.77
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-57.66-57.38-57.31-49.40-48.06-41.69-40.05-39.90
Interest Expense0.000.000.000.00-0.060.070.07
Unusual Expense-0.150.851.652.650.850.901.654.75
Net Income Before Taxes-53.95-54.80-56.74-49.79-45.78-39.48-39.28-42.60
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-53.95-54.80-56.74-49.79-45.78-39.48-39.28-42.60
Net Income From Continuing Operations-53.95-54.80-56.74-49.79-45.78-39.48-39.28-42.60
Net Income-53.95-54.80-56.74-49.79-45.78-39.48-39.28-42.60
EPS (Recurring)-0.36-0.38-0.51-0.51-0.48-0.41-0.57-0.92
EPS (Basic, Before Extraordinaries)-0.36-0.38-0.52-0.53-0.48-0.42-0.59-1.00
EPS (Diluted)-0.36-0.38-0.52-0.53-0.48-0.42-0.59-1.00
EBITDA-57.24-56.99-56.91-48.94-47.68-41.31-39.65-39.41
Non-Operating Income (Expense)3.563.442.222.273.133.172.492.12
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense6.155.625.156.503.933.153.343.82
Shares Outstanding111.56105.1398.3978.9777.8877.6077.4940.47
Market Capitalization800.25983.51708.42439.41480.45377.50286.72159.82

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments189.07148.92123.64213.72207.78154.7483.52122.4669.09
Short Term Receivables0.000.000.000.000.110.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets16.388.386.095.9214.724.162.786.171.56
Total Current Assets205.46157.30129.73219.64222.61158.9086.30128.6470.66
Net Property, Plant & Equipment26.0929.0433.1638.617.6011.7316.6310.422.43
Total Investments and Advances0.771.951.831.832.070.330.330.000.00
Intangible Assets-------0.000.00
Other Assets0.220.370.210.170.090.210.210.543.11
Total Assets232.54188.66164.94260.25232.38171.17103.47139.6076.19
Short Term Debt Incl. Current Port. of LT Debt2.103.022.322.561.502.211.920.170.00
Accounts Payable3.224.242.033.244.463.277.123.695.07
Other Current Liabilities28.1423.0010.1616.7017.6419.009.238.626.21
Total Current Liabilities33.4730.2614.5222.5123.6024.4818.2812.4811.27
Long Term Debt19.0621.1623.9425.980.572.945.150.860.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.100.0011.660.001.070.00
Total Liabilities52.5351.4238.4648.5924.1739.0823.4214.4111.27
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00124.18
Common Equity180.01137.25126.48211.67208.21132.0980.05125.18-59.26
Total Shareholders Equity180.01137.25126.48211.67208.21132.0980.05125.1864.92
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity180.01137.25126.48211.67208.21132.0980.05125.1864.92
Total Liabilities & Stockholders Equity232.54188.66164.94260.25232.38171.17103.47139.6076.19
Book Value Per Share2.283.396.2010.8228.3023.3426.1153.00-26.03
Tangible Book Value Per Share2.283.396.2010.8228.3023.3426.1153.00-26.03
Full-Time Employees12110088871047012111160
Price to Book Ratio2.340.930.850.280.934.872.567.596.35
Return on Assets-82.78-70.53-45.16-34.91-35.78-64.30-96.45-69.32-92.52
Return on Equity-109.90-94.57-56.79-40.96-42.43-83.24-114.24-78.69-207.02
Return on Invested Capital-87.57-78.72-63.83-36.18-34.58-65.39-137.59-59.34-83.24
Quick Ratio6.145.208.949.769.436.494.7210.316.27
Current Ratio6.145.208.949.769.436.494.7210.316.27

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-215.27-174.32-124.70-96.02-85.98-72.19-88.29-117.22-74.80
Depreciation1.671.642.462.582.412.963.922.821.57
Other Funds (Non Cash)26.7423.2219.385.59-10.7114.5011.6113.935.87
Funds from Operations-186.86-149.47-102.86-87.84-94.29-54.72-72.76-100.47-67.36
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-12.06-6.822.85-6.34-3.69-23.0416.167.75-2.83
Cash from Operating Activities-198.92-156.29-100.01-94.18-97.98-77.76-56.60-92.71-70.20
Capital Expenditures-1.38-1.15-0.65-1.51-3.02-1.28-0.90-4.39-7.78
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.090.090.010.0032.120.000.000.00-
Purchase or Sale of Investments-44.20-57.39-15.4411.2030.05-89.817.5028.90-18.99
Purchase of Investments-351.98-235.89-204.34-117.43-182.76-141.25-0.40-31.50-44.32
Sale Or Maturity of Investments307.78178.50188.90128.63212.8151.447.9060.4025.34
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources-0.090.000.000.000.000.000.000.000.00
Cash from Investing Activities-45.58-58.45-16.099.6959.16-91.096.6024.52-26.76
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock308.21194.74122.572.9772.57134.92128.7059.98133.69
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock308.21194.74122.572.9772.57134.92128.7059.98133.69
Proceedsfrom Stock Options497.82194.7413.262.9772.55134.88128.7059.98133.69
Issuance or Reduction of Debt, Net-0.20-0.72-0.470.002.080.000.000.00-0.01
Change in Long Term Debt-0.20-0.72-0.470.002.080.000.000.00-0.01
Issuance of Long Term Debt0.000.000.000.002.140.000.000.000.00
Reduction of Long Term Debt-0.20-0.72-0.470.00-0.070.000.000.00-0.01
Net Financing Active Other Cash Flow0.520.420.340.150.180.070.00-2.10-2.17
Other Financing Activities Uses0.000.000.000.000.000.000.00-2.10-2.17
Cash from Financing Activities308.53194.45122.443.1274.83134.99128.7057.88131.51
Net Change in Cash64.03-20.306.34-81.3736.01-33.8778.70-10.3234.55
Free Cash Flow-200.30-157.44-100.67-95.69-100.99-79.05-57.50-97.10-77.97
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments349.57378.32381.32189.07236.14268.11
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets15.6316.7915.4716.388.7110.53
Total Current Assets365.19395.11396.79205.46244.85278.64
Net Property, Plant & Equipment23.7524.6325.2126.0926.8927.45
Total Investments and Advances0.710.710.710.771.921.92
Other Assets0.250.140.180.220.250.28
Total Assets389.90420.58422.89232.54273.91308.29
Short Term Debt Incl. Current Port. of LT Debt2.282.232.192.102.312.90
Accounts Payable3.234.365.563.228.434.70
Other Current Liabilities24.9421.9922.5328.1425.6022.25
Total Current Liabilities30.4528.5830.2833.4736.3429.85
Long Term Debt17.3417.9218.4819.0619.6220.16
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities47.7946.5148.7652.5355.9750.00
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity342.11374.07374.13180.01217.95258.29
Total Shareholders Equity342.11374.07374.13180.01217.95258.29
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity342.11374.07374.13180.01217.95258.29
Total Liabilities & Stockholders Equity389.90420.58422.89232.54273.91308.29
Book Value Per Share3.073.563.802.282.803.33
Tangible Book Value Per Share3.073.563.802.282.803.33
Full-Time Employees---121--
Price to Book Ratio2.342.633.162.021.851.28
Return on Assets-64.86-56.83-50.02-82.78-68.82-57.15
Return on Equity-76.87-65.50-57.37-109.90-86.83-68.25
Return on Invested Capital-15.01-13.98-14.45-25.01-19.27-14.18
Quick Ratio11.9913.8213.106.146.749.34
Current Ratio11.9913.8213.106.146.749.34

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-53.95-54.80-56.74-49.79-45.78-39.48
Depreciation0.420.390.400.470.380.39
Other Funds (Non Cash)5.165.766.819.014.754.22
Funds from Operations-48.37-48.65-49.54-40.31-40.65-34.87
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital2.82-3.942.31-13.257.17-2.54
Cash from Operating Activities-45.55-52.59-47.23-53.55-33.47-37.41
Capital Expenditures-0.50-0.15-0.17-0.56-0.09-0.38
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.090.000.00
Purchase or Sale of Investments-3.26-133.4444.9247.58-45.19-32.44
Purchase of Investments-92.66-151.94-83.46-23.92-83.19-63.44
Sale Or Maturity of Investments89.4018.50128.3871.5038.0031.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.00-0.090.000.09
Cash from Investing Activities-3.76-133.5944.7647.01-45.27-32.73
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock15.8848.18239.035.121.47-1.71
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock15.8848.18239.035.121.47-1.71
Proceedsfrom Stock Options15.7448.12239.01194.951.47-191.54
Issuance or Reduction of Debt, Net0.000.000.00-0.20-0.24-0.14
Change in Long Term Debt0.000.000.00-0.20-0.24-0.14
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.00-0.20-0.24-0.14
Net Financing Active Other Cash Flow0.000.290.000.230.200.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities15.8848.47239.035.141.18-1.60
Net Change in Cash-33.42-137.71236.56-1.40-77.57-71.75
Free Cash Flow-46.04-52.74-47.40-54.12-33.56-37.79

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3014.61%13.3M91.1M1.17M
2026-10-1514.06%12.3M87.5M1.14M
2026-09-3014.55%12.7M87.5M1.16M
2026-09-1519.55%17.1M87.5M1.53M
2026-08-3118.73%16.4M87.5M1.59M
2026-08-1419.39%16.6M85.7M1.65M
2026-07-3120.00%17.0M85.2M1.71M
2026-07-1522.59%17.7M78.2M1.68M
2026-06-3023.36%18.3M78.2M1.59M
2026-06-1514.85%11.6M78.2M1.14M
2026-05-2912.28%9.6M78.2M1.29M
2026-05-1511.64%9.1M78.2M1.31M
2026-04-3010.38%8.8M84.9M1.31M
2026-04-1512.48%9.4M75.7M1.34M
2026-03-3113.28%10.0M75.7M1.36M
2026-03-1312.89%9.8M75.7M1.29M
2026-02-2715.92%9.5M59.9M1.06M
2026-02-1315.73%9.4M59.9M1.05M
2026-01-3014.84%8.7M58.3M1.08M
2026-01-1514.61%8.6M58.9M1.06M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.004.008.804.900.0003.000.000.989-0.0140.000
call2.003.007.800.000.0000.000.000.982-0.0140.001
call3.002.006.800.0017.6780.000.000.974-0.0140.001
call4.001.005.402.9810.5605.000.000.964-0.0130.001
call5.000.704.900.009.6430.000.000.950-0.0130.001
call6.000.004.900.7011.7424410.000.744-0.0650.004
call7.000.004.900.0111.4896.000.000.860-0.1930.003
call8.000.050.250.280.85920.000.000.559-0.0830.005
call9.000.004.100.001.4750.000.000.263-0.0320.004
call10.000.000.200.051.3231840.000.078-0.0120.002
call11.000.004.100.002.1260.000.000.171-0.0350.003
call12.000.004.100.002.4320.000.000.155-0.0380.003
call13.000.004.100.002.7000.000.000.144-0.0400.003
call14.000.004.100.002.9400.000.000.136-0.0420.003
call15.000.004.100.003.1570.000.000.130-0.0440.003
call16.000.004.100.003.3540.000.000.124-0.0450.002
put1.000.004.100.007.4730.000.00-0.011-0.0140.000
put2.000.004.100.004.9110.000.00-0.018-0.0140.001
put3.000.004.100.003.5320.000.00-0.025-0.0140.001
put4.000.000.050.093.84150.000.00-0.090-0.0410.002
put5.000.000.050.002.7420.000.00-0.127-0.0370.002
put6.000.000.250.302.2814230.00-0.217-0.0430.003
put7.000.004.300.9013.46810.000.00-0.140-0.1920.003
put8.000.004.901.0010.71313.000.00-0.457-0.0760.005
put9.000.004.900.008.6730.000.00-0.748-0.0320.004
put10.000.404.900.006.8140.000.00-0.805-0.0310.003
put11.001.306.000.007.4290.000.00-0.829-0.0340.003
put12.002.207.000.007.8020.000.00-0.845-0.0370.003
put13.003.908.000.008.1330.000.00-0.856-0.0390.003
put14.004.209.000.008.4280.000.00-0.864-0.0410.003
put15.005.2010.000.008.6950.000.00-0.870-0.0420.003
put16.006.2011.000.008.9380.000.00-0.876-0.0430.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-06SCHEDULE 13D/ASEC
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-264Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-204Statement of changes in beneficial ownership of securities2026-10-18SEC
2026-10-064Statement of changes in beneficial ownership of securities2026-10-02SEC
2026-08-14SCHEDULE 13D/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-06424B5SEC
2026-08-06S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuersSEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-06SCHEDULE 13GSEC
2026-07-30SCHEDULE 13GSEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-02SEC
2026-06-24SCHEDULE 13D/ASEC
2026-06-243Initial statement of beneficial ownership of securities2026-06-22SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-108-KCurrent report2026-06-10SEC
2026-06-05424B7SEC
2026-05-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-05SCHEDULE 13G/ASEC
2026-04-27SCHEDULE 13G/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100024.58K1
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-02002.50M19
2026-010037.04K3
2025-1200117.14K4
2025-110013.51K1

Institutional holders

Manager% owned
RA CAPITAL MANAGEMENT, L.P.12.23%
PERCEPTIVE ADVISORS LLC12.09%
Bain Capital Life Sciences Investors, LLC9.96%
Siren, L.L.C.7.81%
BlackRock, Inc.7.04%
FMR LLC6.78%
ARMISTICE CAPITAL, LLC4.35%
STATE STREET CORP4.24%
Jupiter Topco LLC4.11%
VANGUARD CAPITAL MANAGEMENT LLC4.07%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.20%
State Street(R) SPDR(R) S&P(R) Biotech ETF2.62%
Select Biotechnology Portfolio2.43%
iShares Russell 2000 ETF2.09%
Columbia Small Cap Growth Fund1.64%
Franklin Biotechnology Discovery Fund1.43%
Fidelity Small Cap Index Fund0.88%
VANGUARD EXTENDED MARKET INDEX FUND0.79%
Fidelity Advisor Biotechnology Fund0.69%
iShares Biotechnology ETF0.56%

OakChart. SLDB. Cached 15 minutes.